PF-3922 Phase 1 trial

Abstract # 8018 is about a Phase 1 study of PF- 06463922 (3922). 22 patients were studied (18 ALK+ & 4 ROS1+). 17 had central nervous system (CNS) metastases and 19 had prior ALK inhibitor treatment (either 1 or 2).

Of 15 patients evaluated for efficacy 40% had partial responses. While this is lower than a few of the second generation of ALK inhibitors, remember this is a third generation inhibitor where patients may have had two previous ALK inhibitors.

This entry was posted in Brain metastases, lorlatinib - Lorbrena by Pfizer, Lung cancer, Potential Treatments, Research. Bookmark the permalink.

Leave a Reply